Last Close
Apr 08  •  04:00PM ET
3.37
Dollar change
-0.03
Percentage change
-0.88
%
Index
-
P/E
-
EPS (ttm)
-0.78
Insider Own
0.18%
Shs Outstand
37.48M
Perf Week
-9.41%
Market Cap
126.31M
Forward P/E
-
EPS next Y
-0.57
Insider Trans
0.00%
Shs Float
37.41M
Perf Month
-19.57%
Enterprise Value
133.54M
PEG
-
EPS next Q
-0.22
Inst Own
38.98%
Perf Quarter
-10.61%
Income
-29.10M
P/S
1.79
EPS this Y
8.08%
Inst Trans
2.83%
Perf Half Y
46.98%
Sales
70.54M
P/B
6.51
EPS next Y
22.87%
ROA
-34.62%
Perf YTD
2.43%
Book/sh
0.52
P/C
6.18
EPS next 5Y
14.61%
ROE
-94.24%
52W High
5.05 -33.27%
Perf Year
131.62%
Cash/sh
0.55
P/FCF
-
EPS past 3/5Y
-106.02% -63.72%
ROIC
-77.10%
52W Low
1.21 178.51%
Perf 3Y
-68.36%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
6.90% 8.30%
Gross Margin
42.55%
Volatility
9.26% 9.69%
Perf 5Y
-63.69%
Dividend TTM
-
EV/Sales
1.89
EPS Y/Y TTM
-35.68%
Oper. Margin
-34.90%
ATR (14)
0.34
Perf 10Y
-13.14%
Dividend Ex-Date
-
Quick Ratio
1.19
Sales Y/Y TTM
-
Profit Margin
-41.26%
RSI (14)
35.80
Dividend Gr. 3/5Y
- -
Current Ratio
1.54
EPS Q/Q
-355.42%
SMA20
-9.86%
Beta
-0.02
Payout
-
Debt/Eq
1.43
Sales Q/Q
0.88%
SMA50
-18.71%
Rel Volume
0.12
Prev Close
3.40
Employees
289
LT Debt/Eq
0.94
SMA200
22.93%
Avg Volume
64.95K
Price
3.37
IPO
Aug 01, 1997
Option/Short
Yes / Yes
Trades
Volume
7,736
Change
-0.88%
Date Action Analyst Rating Change Price Target Change
May-15-25Downgrade Piper Sandler Overweight → Neutral
Apr-04-25Downgrade Jefferies Buy → Hold $2
Nov-01-22Initiated Jefferies Buy $11
Apr-28-21Initiated Piper Sandler Overweight $13
Apr-15-20Initiated B. Riley FBR Buy $5.50
Jul-28-14Downgrade Northland Capital Outperform → Market Perform $6 → $3.50
Jun-16-14Initiated H.C. Wainwright Buy $6
Mar-05-13Initiated Northland Capital Outperform $6
Nov-18-10Reiterated Morgan Joseph Buy $3 → $5.25
Aug-20-09Reiterated Roth Capital Hold $2.50 → $5
Mar-25-26 03:01PM
07:30AM
Mar-10-26 07:30AM
Mar-09-26 08:17AM
Mar-04-26 07:30AM
07:30AM Loading…
Feb-12-26 07:30AM
Jan-12-26 07:30AM
Dec-30-25 10:42AM
Dec-26-25 12:20PM
Dec-11-25 10:06AM
Nov-20-25 07:30AM
Nov-18-25 07:00AM
Nov-06-25 04:00PM
07:30AM
Nov-04-25 07:00AM
07:00AM Loading…
Oct-27-25 07:00AM
Oct-23-25 07:00AM
Oct-20-25 08:30AM
Oct-17-25 09:50AM
Sep-30-25 07:00AM
Sep-16-25 07:00AM
Sep-08-25 07:00AM
Aug-28-25 07:00AM
Aug-27-25 09:29AM
Aug-26-25 07:00AM
Aug-25-25 07:00AM
Aug-07-25 07:00AM
Jul-04-25 04:19AM
Jul-01-25 07:00AM
May-27-25 07:00AM
03:09AM Loading…
May-16-25 03:09AM
May-15-25 07:00AM
May-14-25 09:56AM
May-01-25 07:00AM
Apr-30-25 09:01AM
Apr-29-25 09:05AM
07:00AM
Apr-28-25 01:19PM
Apr-24-25 07:00AM
Apr-22-25 07:00AM
Mar-28-25 03:01AM
Mar-27-25 11:56AM
07:10AM
Mar-06-25 07:00AM
Mar-03-25 07:00AM
Feb-06-25 08:00AM
Jan-13-25 07:00AM
Jan-10-25 07:00AM
Jan-08-25 07:00AM
Dec-04-24 09:10AM
Dec-02-24 07:00AM
Nov-27-24 07:00AM
Nov-22-24 08:00AM
Nov-19-24 08:00AM
Nov-08-24 06:02AM
Nov-07-24 07:00AM
Nov-06-24 08:00AM
07:50AM
Oct-30-24 01:01AM
Oct-24-24 08:00AM
Oct-01-24 07:00AM
Sep-19-24 08:00AM
Aug-29-24 08:00AM
Aug-28-24 07:00AM
Aug-07-24 07:00AM
Aug-06-24 07:00AM
Jul-22-24 06:33AM
Jul-19-24 04:15PM
Jul-08-24 07:00AM
Jun-03-24 08:00AM
May-22-24 08:00AM
May-17-24 08:10AM
May-16-24 12:52PM
08:00AM
May-06-24 08:00AM
May-02-24 08:00AM
Apr-23-24 08:00AM
Mar-29-24 09:44AM
Mar-27-24 11:53AM
07:00AM
Mar-13-24 07:00AM
Mar-06-24 07:00AM
Mar-04-24 07:00AM
Feb-29-24 07:00AM
Feb-01-24 08:00AM
Jan-08-24 08:00AM
Jan-02-24 08:00AM
Dec-12-23 08:00AM
Dec-06-23 04:30PM
Nov-30-23 08:00AM
Nov-20-23 08:00AM
Nov-10-23 03:33PM
Nov-09-23 06:00AM
Nov-06-23 08:00AM
Oct-26-23 08:00AM
Sep-06-23 08:00AM
Aug-25-23 09:06AM
Aug-24-23 06:30AM
Aug-10-23 08:00AM
Jul-26-23 08:00AM
EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.